Humoral Immune Responses against the Mycobacterium tuberculosis 38-Kilodalton, MTB48, and CFP-10/ESAT-6 Antigens in Tuberculosis

Institute for Tuberculosis Research, 309th Hospital of Chinese PLA, Beijing 100091, China.
Clinical and vaccine Immunology: CVI (Impact Factor: 2.47). 03/2010; 17(3):372-5. DOI: 10.1128/CVI.00287-09
Source: PubMed


The diagnosis of smear-negative and culture-negative patients with active tuberculosis (TB) is challenging. The detection of Mycobacterium tuberculosis-specific antibodies in human sera has been an important diagnostic aid. However, detection of antibody responses to a single antigen usually has a low sensitivity for diagnosis of TB. In this study, humoral immune responses against recombinant M. tuberculosis 38-kDa, MTB48, and CFP-10/ESAT-6 (culture filtrate protein 10/6-kDa early secreted antigen target of M. tuberculosis) antigens in 250 Chinese TB patients and 260 healthy subjects were evaluated by an enzyme-linked immunosorbent assay (ELISA). The levels of antibodies against those antigens in TB patients, even in bacterium-negative ones, were significantly higher than those in healthy subjects (P < 0.001). The serodiagnostic sensitivities to detect antibodies against individual antigens, i.e., recombinant M. tuberculosis 38-kDa, MTB48, and CFP-10/ESAT-6 antigens, in TB patients were 73.6%, 73.2%, and 60.4%, respectively, with specificities of 85.4%, 77.7%, and 73.8%, respectively. Importantly, the sensitivity to positively detect humoral responses to one of the antigens increased further. Our data suggest that the humoral immune responses to M. tuberculosis antigens in TB patients are heterogeneous. The 38-kDa, MTB48, and CFP-10/ESAT-6 antigens can be used as the cocktail antigens in the serodiagnosis of active TB, especially for smear- or culture-negative TB cases.

Download full-text


Available from: Xueqiong Wu, Oct 05, 2015
15 Reads
  • Source
    • "Rv2241 was the most immunogenic protein studied, with some potential in terms of practical application as biomarker. Interestingly, Rv2241 is a secreted protein, a feature that has been previously highlighted regarding humoral immune responses in human TB [21] [22] [23] [24] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Molecular epidemiology has revealed that Mycobacterium tuberculosis (Mtb), formerly regarded as highly conserved species, displays a considerable degree of genetic variability that can influence the outcome of the disease as well as the innate and adaptive immune response. Recent studies have demonstrated that Mtb families found worldwide today differ in pathology, transmissibility, virulence, and development of immune response. By proteomic approaches seven proteins that were differentially expressed between a local clinical isolate from Latin-American-Mediterranean (LAM) and from Haarlem (H) lineages were identified. In order to analyze the immunogenic ability, recombinant Rv2241, Rv0009, Rv0407, and Rv2624c proteins were produced for testing specific antibody responses. We found that these proteins induced humoral immune responses in patients with drug-sensitive and drug-resistant tuberculosis with substantial cross-reactivity among the four proteins. Moreover, such reactivity was also correlated with anti-Mtb-cell surface IgM, but not with anti-ManLAM, anti-PPD, or anti-Mtb-surface IgG antibodies. Therefore, the present results describe new Mtb antigens with potential application as biomarkers of TB.
    BioMed Research International 07/2014; 2014:741309. DOI:10.1155/2014/741309 · 3.17 Impact Factor
  • Source
    • "A range of known antigens has been tested for immunogenicity as mixtures, fusion proteins and peptides. These include chimeric Ag85B/ESAT6 with adjuvants monophosphoryl lipid A (MPL) and trehalose 6,6'-dimycolate,15 hsp16.3 with dimethyl-dioctadecyl-ammonium bromide/MPL (DDA/MPL) adjuvant,16 fusion protein M. tuberculosis protein 64 (MPT64)–ESAT6,17 resuscitation-promoting factor B (Rv1009),18 or CFP10, ESAT6 or RpfE (Rv2450) with nitrocellulose,19,20 or Rv377221 and Rv342522 with incomplete Freund's adjuvant; or Ag85B/MPT64190–198/Mtb8.4 plus a novel adjuvant of DDA with BCG extract.23 In-silico analysis of putative MHC Class 1-restricted epitopes present in antigens encoded within the region of difference 1 (RD-1) to RD-16 regions of M. bovis genome has revealed potential high-affinity HLA binders24 and profiles of human humoral responses to 38-kDa, MTB48, CFP10/ESAT6 antigens have been defined.25 Screening of human immune sera against an expression library of M. tuberculosis open reading frames revealed three novel antigens among the top 20 most strongly recognized: Rv1987, Rv3807c and Rv3887c.26 "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is now privately acknowledged that there may be little if any perceptible impact of the national Bacille Calmette–Guerin (BCG) vaccination program on disease prevalence, despite the extensive coverage of the newborn infant population and likely benefit in the early years of life. A better preventive vaccine than BCG is now being sought by Chinese researchers. Urgency has been added to the control problem by the emergence of multidrug-resistant tuberculosis (TB). Furthermore, expensive second-line drugs seem unlikely to be made available by the government to treat drug-resistant cases, so attention in addition has turned to the potential of immunotherapy as an adjunct to chemotherapy. Research trends are summarized here.
    Emerging Microbes and Infections 07/2012; 1(7). DOI:10.1038/emi.2012.3 · 2.26 Impact Factor
  • Source
    • "Approximately 90% of patients produce antibodies to Mtb proteins with antibody profiles showing great inter-individual variation. So far, a clear correlation between antibody profiles and disease status has not been clearly established, making its use for routine diagnostics problematic (Lyashchenko et al., 1998; Wu et al., 2010). Recently, a major contribution to the field has been published by Kunnath-Velayudhan and colleagues (Kunnath-Velayudhan et al., 2010). "
    Understanding Tuberculosis - Global Experiences and Innovative Approaches to the Diagnosis, 02/2012; , ISBN: 978-953-307-938-7
Show more